From WikiProjectMed
Jump to navigation Jump to search
Trade namesStarlix
  • (2R)-2-({[trans-4-(1-methylethyl)cyclohexyl]carbonyl}amino)-3-phenylpropanoic acid
Clinical data
Drug classMeglitinide[1]
Main usesType 2 diabetes[2]
Side effectsDizziness, diarrhea, bronchitis, low blood sugar[2]
Routes of
By mouth
Typical dose60 to 180 mg TID[1]
External links
License data
Legal status
Protein binding98%
Elimination half-life1.5 hours
Chemical and physical data
Molar mass317.429 g·mol−1
3D model (JSmol)
  • O=C(N[C@H](Cc1ccccc1)C(O)=O)[C@H]2CC[C@@H](CC2)C(C)C
  • InChI=1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15-,16-,17-/m1/s1 checkY

Nateglinide, sold under the brand name Starlix, is a medication used to treat type 2 diabetes.[2] It is used together with diet and exercise.[2] It is not a first line treatment, though may be added to metformin.[2][3] It is taken by mouth.[2]

Common side effects include dizziness, diarrhea, bronchitis, and low blood sugar.[2] Use is not recommended in those with significant liver problems.[3] Safety in pregnancy is not clear.[2] It belongs to the meglitinide class and works by stimulating the release of insulin.[1]

Nateglinide was approved for medical use in the United States in 2000 and Europe in 2001.[2][3] In the United States it costs about 30 USD per month as of 2021.[4] It is not available in the United Kingdom as of 2021.[1]

Medical uses


It is generally take at a dose of 60 to 180 mg half an hour before meals three times per day.[1]

Nateglinide is delivered in 60 mg & 120 mg tablet form.


Nateglinide is contraindicated in patients who:


Anti-diabetic drug Nateglinide pathway[5]

Nateglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the β cells.

This depolarizes the β cells and causes voltage-gated calcium channels to open. The resulting calcium influx induces fusion of insulin-containing vesicles with the cell membrane, and insulin secretion occurs.

See also


  1. 1.0 1.1 1.2 1.3 1.4 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 742. ISBN 978-0857114105.
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 "Nateglinide Monograph for Professionals". Archived from the original on 2 September 2019. Retrieved 12 November 2021.
  3. 3.0 3.1 3.2 "Starlix". Archived from the original on 12 November 2020. Retrieved 12 November 2021.
  4. "Nateglinide Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 25 April 2020. Retrieved 12 November 2021.
  5. "Anti-diabetic Drug Nateglinide Pathway, Pharmacokinetics". PharmGKB.

External links